Sanofi (NASDAQ: SNY), the France-based pharmaceutical giant, is reportedly in talks with potential buyers for Amunix Pharmaceuticals, an immuno-oncology company it acquired in 2021, according to Endpoints News. This move aligns with Sanofi’s 2023 earnings report, which outlined plans to shift resources away from oncology to bolster its immunology pipeline, aiming to streamline costs.
Sanofi initially acquired the U.S. biotechnology firm for $1 billion upfront, with an additional $225 million in potential milestone payments. The acquisition included one site and assets such as a HER2-targeted T-cell engager currently in Phase I trials for locally advanced or metastatic HER2-expressing cancers.
Last year, Sanofi also scaled back its oncology programs stemming from its acquisitions of Principia Biopharma and Kymab, along with a collaboration with Denali Therapeutics.- Flcube.com
